Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) defined by the
triad of hemolytic anemia, thrombocytopenia, and acute kidney injury. Microthrombi develop …

Thrombotic microangiopathy is a rare but serious complication that affects kidney transplant
recipients. It appears in 0.8–14% of transplanted patients and negatively affects graft and …

Introduction Since 2016, kidney transplantation in patients with atypical hemolytic uremic
syndrome (aHUS) in the Netherlands is performed without eculizumab prophylaxis …

Purpose Inherited kidney diseases are among the leading causes of kidney failure in
children, resulting in increased mortality, high healthcare costs and need for organ …

Background The long-term mortality of kidney transplantation patients with atypical
hemolytic uremic syndrome remains high, and the efficacy of the main treatment eculizumab …

Introduction Posttransplant thrombotic microangiopathy (PT-TMA) is an uncommon event
that characterizes approximately 3% to 14% of kidney transplants (KTs), and that is …

We hereby present a case of an atypical hemolytic uremic syndrome (aHUS) precipitated by
coronavirus disease 2019 (COVID-19). A 26-year-old male was diagnosed with COVID-19 …

Hereditary forms of hemolytic uremic syndrome (HUS), formerly known as atypical HUS,
typically involve mutations in genes encoding for components of the alternative pathway of …

Background Despite significant advances in therapeutic management of atypical hemolytic
uremic syndrome (aHUS), guidelines are not timely updated and achieving a consensus on …

De novo thrombotic microangiopathy (TMA) is a rare and challenging condition in kidney
transplant recipients, with limited research on its incidence and impact on graft survival. This …